Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells.


Journal

Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 02 11 2022
accepted: 27 01 2023
medline: 24 7 2023
pubmed: 16 2 2023
entrez: 15 2 2023
Statut: ppublish

Résumé

Visceral obesity is a key risk factor in the development of oesophagogastric junctional adenocarcinoma (OGJ), predominantly via generation of systemic low grade inflammation. Obesity-induced inflammation promotes resistance to current standards of care, enhancing tumour cell growth and survival. This study investigates the effect of the visceral adipose tissue secretome from OGJ patients with early versus advanced tumours on T-cell immunity and the role of immune checkpoint blockade in enhancing anti-tumour immunity. Visceral adipose conditioned media (ACM) from both early and late-stage OGJ patients significantly altered T cell activation status, upregulating co-stimulatory marker CD27 on T cells. ACM from both early and late-stage OGJ patients significantly altered immune checkpoint expression profiles downregulating immune checkpoints (ICs) on the surface of dual Th1/17-like and Th17-like cells and upregulating ICs on the surface of Th1-like cells and Treg cells. ACM derived from early-stage OGJ patients but not late-stage OGJ patients increased IFN-γ production by T cells. The addition of immune checkpoint blockers (ICBs) did not increase IFN-γ production by T cells in the presence of late-stage ACM, collectively highlighting the dichotomous immunostimulatory effect of early-stage ACM and immune-inhibitory effect of late-stage ACM. Interestingly, ACM from early-stage OGJ patients was more pro-inflammatory than ACM from late-stage patients, reflected by decreased levels of IL-17A/F, TNF-α, IL-1RA and IL-5. The ACM-induced upregulation of ICs on T cells highlights a therapeutic vulnerability that could be exploited by ICBs to harness anti-cancer immunity and improve clinical outcomes for OGJ patients. Schematic workflow - (A) visceral adipose tissue was taken from OAC patients at time of surgery and cultured for 72 h in media. (B) The harvested ACM was co-cultured with healthy donor PBMCs that were concurrently activated with anti-CD3/28 for 48 h and T cell immunophenotyping was carried out by flow cytometry. Key findings - (A) Early and late stage ACM enhanced a Th1-like phenotype and upregulated CTLA-4 on Th1-like cells. A Th17-like phenotype was also enhanced in addition with a Treg-like phenotype. CTLA-4 and PD-L1 were upregulated on the surface of Treg-like cells. (B) ICB-attenuated IL-17 production by T cells. However, ACM attenuated ICB-mediated reduction in IL-10 production by T cells. Higher levels of pro-inflammatory factors were found in early stage ACM compared with late stage ACM.

Identifiants

pubmed: 36790524
doi: 10.1007/s00432-023-04620-6
pii: 10.1007/s00432-023-04620-6
pmc: PMC10356656
doi:

Substances chimiques

CTLA-4 Antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6583-6599

Informations de copyright

© 2023. The Author(s).

Références

Immunology. 2011 Apr;132(4):475-81
pubmed: 21323663
Cell Oncol (Dordr). 2020 Feb;43(1):1-18
pubmed: 31900901
Nat Rev Clin Oncol. 2016 Mar;13(3):185-98
pubmed: 26573424
Immunol Today. 1994 Jul;15(7):307-11
pubmed: 8086099
Int Immunol. 2008 Apr;20(4):471-83
pubmed: 18272926
Science. 2021 Aug 13;373(6556):760-767
pubmed: 34385390
Oncogenesis. 2018 Dec 19;7(12):97
pubmed: 30563983
Nat Med. 2019 Jan;25(1):141-151
pubmed: 30420753
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Cancer Res. 2015 Sep 15;75(18):3788-99
pubmed: 26208902
Sci Transl Med. 2011 Nov 30;3(111):111ra120
pubmed: 22133721
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33229508
Br J Cancer. 2021 Aug;125(4):479-494
pubmed: 33903730
Br J Pharmacol. 2009 Oct;158(3):779-89
pubmed: 19702783
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
JAMA Oncol. 2019 Apr 01;5(4):546-550
pubmed: 30570649
Future Oncol. 2018 Feb;14(5):417-430
pubmed: 29094609
Br J Surg. 2010 Jul;97(7):1020-7
pubmed: 20632267
Oncotarget. 2016 Apr 19;7(16):21853-64
pubmed: 26942702
Biochim Biophys Acta. 2013 Oct;1831(10):1533-41
pubmed: 23500888
Nat Rev Endocrinol. 2019 Mar;15(3):139-154
pubmed: 30459447
World J Gastrointest Oncol. 2021 May 15;13(5):312-331
pubmed: 34040696
Cancers (Basel). 2018 Dec 27;11(1):
pubmed: 30591653
J Leukoc Biol. 2016 Dec;100(6):1435-1442
pubmed: 27365528
Endocr Relat Cancer. 2011 Jul 11;18(4):C25-9
pubmed: 21680729
J Leukoc Biol. 2017 Aug;102(2):293-306
pubmed: 28522598
J Autoimmun. 2013 Sep;45:49-57
pubmed: 23849743
Horm Mol Biol Clin Investig. 2015 Jan;21(1):57-74
pubmed: 25781552
Nat Rev Gastroenterol Hepatol. 2014 Sep;11(9):525-34
pubmed: 24860927
Tissue Antigens. 2007 Jul;70(1):1-11
pubmed: 17559575
Cancer Discov. 2016 Aug;6(8):852-69
pubmed: 27246539
J Immunother Cancer. 2019 Aug 19;7(1):222
pubmed: 31426863
Oncogene. 2016 Oct 13;35(41):5337-5349
pubmed: 26923327
J Mol Endocrinol. 2019 Apr 1;62(3):R201-R222
pubmed: 30620711
Oncol Lett. 2016 Feb;11(2):925-932
pubmed: 26893670
J Exp Med. 1998 Dec 21;188(12):2357-68
pubmed: 9858522
Obes Rev. 2010 Dec;11(12):863-74
pubmed: 20149119
J Cancer. 2016 Nov 26;7(15):2346-2359
pubmed: 27994674
Nat Rev Gastroenterol Hepatol. 2018 Nov;15(11):699-714
pubmed: 30323319
Asian J Surg. 2018 May;41(3):210-215
pubmed: 27986415
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Crit Rev Eukaryot Gene Expr. 2010;20(2):87-103
pubmed: 21133840
J Exp Med. 2020 Jan 6;217(1):
pubmed: 31727783
Front Oncol. 2020 Jun 04;10:891
pubmed: 32582553
Cancer Metastasis Rev. 2021 Mar;40(1):31-46
pubmed: 33009650
Int J Mol Sci. 2021 Jan 22;22(3):
pubmed: 33499003
Life Sci. 2015 Oct 15;139:16-23
pubmed: 26297445

Auteurs

Maria Davern (M)

Cancer Immunology and Immunotherapy Group, Department of Surgery, School of Medicine, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Dublin 8, Ireland.

Dara Bracken-Clarke (D)

Cancer Immunology and Immunotherapy Group, Department of Surgery, School of Medicine, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Dublin 8, Ireland.

Noel E Donlon (NE)

Cancer Immunology and Immunotherapy Group, Department of Surgery, School of Medicine, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Dublin 8, Ireland.

Andrew D Sheppard (AD)

Cancer Immunology and Immunotherapy Group, Department of Surgery, School of Medicine, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Dublin 8, Ireland.

Fiona O' Connell (FO)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Aisling B Heeran (AB)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Klaudia Majcher (K)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Melissa J Conroy (MJ)

Cancer Immunology and Immunotherapy Group, Department of Surgery, School of Medicine, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Dublin 8, Ireland.

Eimear Mylod (E)

Cancer Immunology and Immunotherapy Group, Department of Surgery, School of Medicine, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Dublin 8, Ireland.

Christine Butler (C)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Claire Donohoe (C)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Dearbhaile O' Donnell (DO)

Department of Clinical Medicine, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Dublin 8, Ireland.

Maeve Lowery (M)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Anshul Bhardwaj (A)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Narayanasamy Ravi (N)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Ashanty A Melo (AA)

Cancer Immunology and Immunotherapy Group, Department of Surgery, School of Medicine, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Dublin 8, Ireland.

Jacintha O' Sullivan (JO)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

John V Reynolds (JV)

Department of Surgery, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, St. James's Hospital, Trinity College Dublin, Dublin, Ireland.

Joanne Lysaght (J)

Cancer Immunology and Immunotherapy Group, Department of Surgery, School of Medicine, Trinity St. James's Cancer Institute, Trinity Translational Medicine Institute, Dublin 8, Ireland. jlysaght@tcd.ie.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH